Jamaica vs Kyrgyzstan: Share of the population living with HIV receiving antiretroviral therapy
Jamaica
54.1%
in 2024
Kyrgyzstan
52.5%
in 2024
Jamaica rank
119th
Kyrgyzstan rank
121st
Share of the population living with HIV receiving antiretroviral therapy over time
- Jamaica
- Kyrgyzstan
How they compare
Jamaica currently reports 54.1% against 52.5% in Kyrgyzstan, a difference of 1.6%.
The two have swapped places 1 time across 27 shared years of data; in 1998 it was Kyrgyzstan ahead.
Jamaica ranks 119th and Kyrgyzstan ranks 121st of 149 countries.
Jamaica has averaged higher in every one of the 4 decades both report.
Head to head by decade
| Decade | Jamaica | Kyrgyzstan | Difference | Ahead |
|---|---|---|---|---|
| 1990s | 0.0% | 0.0% | 0.0% | — |
| 2000s | 5.4% | 2.0% | 3.4% | Jamaica |
| 2010s | 34.1% | 24.6% | 9.5% | Jamaica |
| 2020s | 50.9% | 47.5% | 3.4% | Jamaica |
Averages of every year both report within each decade.
Frequently asked questions
- Which has higher share of the population living with hiv receiving antiretroviral therapy, Jamaica or Kyrgyzstan?
- Jamaica, at 54.1% against 52.5% in Kyrgyzstan as of 2024.
- What is the difference in share of the population living with hiv receiving antiretroviral therapy between Jamaica and Kyrgyzstan?
- 1.6%, with Jamaica ahead.
- How many years of comparable data are there for Jamaica and Kyrgyzstan?
- 27 years are reported by both, from 1998 to 2024.
- How do Jamaica and Kyrgyzstan rank globally for share of the population living with hiv receiving antiretroviral therapy?
- Jamaica ranks 119th and Kyrgyzstan ranks 121st of 149 countries.
- Where does this data come from?
- Joint United Nations Programme on HIV/AIDS (2026) – with minor processing by Our World in Data, published as Share of the population living with HIV receiving antiretroviral therapy. Statizoid refreshes it automatically from the source and publishes the full history for both places.
Individual pages
About this data
Percentage of individuals diagnosed with HIV who are currently receiving antiretroviral therapy. This is the central estimate.